Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 11.04%1.21B | -11.71%1.06B | -10.94%871.62M | 23.68%4.25B | -3.52%977.04M | 3.99%1.09B | 74.65%1.2B | 42.81%978.69M | 25.34%3.44B | 5.83%1.01B |
| Cost of revenue | 5.90%795.15M | -9.07%700.92M | -12.86%588.29M | 19.21%2.89B | -5.30%697.52M | 6.22%750.84M | 53.49%770.86M | 39.96%675.09M | 26.75%2.43B | 11.20%736.54M |
| Gross profit | 22.35%417.25M | -16.42%361.33M | -6.68%283.33M | 34.44%1.36B | 1.22%279.52M | -0.60%341.04M | 131.58%432.32M | 49.56%303.61M | 22.06%1.01B | -6.25%276.16M |
| Operating expense | -9.91%129.49M | 19.63%115.66M | -11.94%94.24M | 26.74%456.82M | -28.89%109.29M | 61.50%143.73M | 37.34%96.68M | 19.65%107.03M | 5.94%360.43M | 37.96%153.69M |
| Selling and administrative expenses | -5.16%135.82M | 23.75%123.76M | -6.74%100.82M | 24.94%490.66M | 13.25%139.32M | 49.96%143.22M | 17.95%100.01M | 20.92%108.11M | 8.76%392.72M | 0.72%123.02M |
| -Selling and marketing expense | 5.18%42.66M | 34.27%42.46M | -27.27%27.69M | 7.05%160.42M | 9.77%50.16M | 9.60%40.56M | -16.40%31.62M | 29.83%38.08M | 26.93%149.86M | 6.55%45.7M |
| -General and administrative expense | -9.25%93.16M | 18.88%81.3M | 4.42%73.13M | 35.98%330.24M | 15.30%89.16M | 75.50%102.66M | 45.62%68.39M | 16.57%70.03M | -0.07%242.87M | -2.44%77.33M |
| Other operating expenses | ---- | ---- | ---- | 88.41%-1.28M | ---- | --510K | ---- | -2,508.89%-1.08M | -2,287.23%-11.03M | --30.67M |
| Total other operating income | --6.33M | 143.42%8.1M | 507.29%6.58M | 53.17%32.56M | --30.03M | ---- | -76.88%3.33M | --1.08M | 4.09%21.26M | ---- |
| Operating profit | 45.84%287.76M | -26.81%245.67M | -3.81%189.09M | 38.73%899.67M | 39.00%170.23M | -22.35%197.31M | 188.62%335.64M | 73.13%196.58M | 33.34%648.52M | -33.13%122.47M |
| Net non-operating interest income (expenses) | -57.74%5.59M | -41.00%7.15M | 47.52%11.84M | 5.67%42.26M | -52.71%8.89M | 967.47%13.23M | -9.02%12.11M | 20.96%8.03M | 363.81%39.99M | 155.20%18.81M |
| Non-operating interest income | -6.13%24.41M | -10.02%23.29M | -5.11%23.63M | -8.39%97.93M | -7.15%25.9M | -6.83%26M | -13.11%25.88M | -11.25%24.91M | 4.70%106.9M | 8.55%27.9M |
| Non-operating interest expense | 47.30%18.82M | 17.22%16.14M | -30.15%11.79M | -66.49%-58.94M | 87.05%17.01M | -52.09%12.78M | -16.42%13.77M | -21.23%16.88M | -445.13%-35.4M | 111.14%9.09M |
| Total other finance cost | ---- | ---- | ---- | 12.02%114.61M | ---- | ---- | ---- | ---- | 2.33%102.31M | ---- |
| Net investment income | 133.49%8.26M | 52.36%-24.65M | ||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | 31.48%-31.83M | 60.19%-34.48M | 8.15%-21.5M | -240.44%-179.55M | -257.52%-23.09M | -124.35%-46.45M | -348.67%-86.61M | 14.54%-23.41M | -102.12%-52.74M | 62.49%14.66M |
| Special income (charges) | 516.18%8.31M | -104.96%-2M | ||||||||
| Less:Impairment of capital assets | ---- | ---- | ---- | 260.11%1.91M | ---- | ---- | ---- | ---- | 17,533.33%529K | ---- |
| Less:Other special charges | ---- | ---- | ---- | -796.11%-10.21M | ---- | ---- | ---- | ---- | 103.65%1.47M | ---- |
| Less:Write off | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Other non-operating income (expenses) | -103.05%-803K | -89.86%446K | 140.94%165K | -6.09%1.11M | -193.59%-12.75M | 529.74%26.34M | 10.28%4.4M | -107.83%-403K | -20.19%1.18M | 126.06%13.63M |
| Income before tax | 36.92%260.72M | -17.61%218.78M | -0.66%179.6M | 27.81%780.05M | -15.50%143.28M | -16.67%190.43M | 132.34%265.54M | 84.61%180.8M | 33.00%610.31M | 24.91%169.56M |
| Income tax | 52.81%88.46M | -28.61%71.26M | 7.46%57.45M | 36.14%262.45M | 41.12%51.29M | -31.29%57.89M | 181.57%99.81M | 45.50%53.46M | 31.00%192.78M | -8.60%36.34M |
| Net income | 29.97%172.26M | -10.99%147.52M | -4.07%122.15M | 23.97%517.6M | -30.95%91.99M | -8.14%132.54M | 110.21%165.73M | 108.09%127.34M | 33.95%417.53M | 38.79%133.22M |
| Net income continuous operations | 29.97%172.26M | -10.99%147.52M | -4.07%122.15M | 23.97%517.6M | -30.95%91.99M | -8.14%132.54M | 110.21%165.73M | 108.09%127.34M | 33.95%417.53M | 38.79%133.22M |
| Noncontrolling interests | -5.79%4.04M | 5.46%3.98M | -0.37%3.74M | 60.14%15.4M | 83.01%3.59M | 771.47%4.28M | -51.49%3.77M | 618.55%3.76M | 332.21%9.62M | 127.35%1.96M |
| Net income attributable to the company | 31.17%168.23M | -11.37%143.54M | -4.19%118.41M | 23.11%502.2M | -32.65%88.41M | -11.50%128.26M | 127.89%161.96M | 103.69%123.58M | 29.15%407.91M | 27.25%131.26M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 31.17%168.23M | -11.37%143.54M | -4.19%118.41M | 23.11%502.2M | -32.65%88.41M | -11.50%128.26M | 127.89%161.96M | 103.69%123.58M | 29.15%407.91M | 27.25%131.26M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 30.69%0.0247 | -11.34%0.0211 | -4.40%0.0174 | 23.00%0.0738 | -32.64%0.013 | -10.00%0.0189 | 138.00%0.0238 | 102.22%0.0182 | 30.43%0.06 | 28.67%0.0193 |
| Diluted earnings per share | 30.69%0.0247 | -11.34%0.0211 | -4.40%0.0174 | 23.00%0.0738 | -32.64%0.013 | -10.00%0.0189 | 138.00%0.0238 | 102.22%0.0182 | 30.43%0.06 | 28.67%0.0193 |
| Dividend per share | 0.015 | 0 | 0.015 | 50.00%0.03 | 0.015 | 0 | 0.015 | 0 | 100.00%0.02 | 0 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.